282 related articles for article (PubMed ID: 15951306)
1. Bortezomib treatment followed by a second non-myeloablative allogeneic stem cell transplant in two previously autografted patients with multiple myeloma relapse.
Mattei D; Mordini N; Vigna Taglianti R; Bruno B; Rapezzi D; Gallamini A
Haematologica; 2005 Jun; 90(6):861-2. PubMed ID: 15951306
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation.
Patriarca F; Prosdocimo S; Tomadini V; Vasciaveo A; Bruno B; Fanin R
Haematologica; 2005 Feb; 90(2):278-9. PubMed ID: 15710593
[TBL] [Abstract][Full Text] [Related]
3. [Bortezomib plus dexamethasone treatment followed by reduced-intensity allogeneic stem cell transplantation for multiple myeloma refractory to high-dose chemotherapy with autologous transplantation].
Hayashi T; Yasui H; Kawakami K; Ikeda H; Takahashi F; Kobayashi T; Nishimura S; Ishida T; Imai K; Shinomura Y
Rinsho Ketsueki; 2011 Mar; 52(3):136-41. PubMed ID: 21471701
[TBL] [Abstract][Full Text] [Related]
4. High complete remission rate and durable remissions achieved with rational use of autologous stem-cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Clin Transplant; 2009; 23(6):839-47. PubMed ID: 20447186
[TBL] [Abstract][Full Text] [Related]
5. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma.
El-Cheikh J; Michallet M; Nagler A; de Lavallade H; Nicolini FE; Shimoni A; Faucher C; Sobh M; Revesz D; Hardan I; Fürst S; Blaise D; Mohty M
Haematologica; 2008 Mar; 93(3):455-8. PubMed ID: 18287132
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability.
Patriarca F; Einsele H; Spina F; Bruno B; Isola M; Nozzoli C; Nozza A; Sperotto A; Morabito F; Stuhler G; Festuccia M; Bosi A; Fanin R; Corradini P
Biol Blood Marrow Transplant; 2012 Apr; 18(4):617-26. PubMed ID: 21820394
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation.
Bruno B; Patriarca F; Sorasio R; Mattei D; Montefusco V; Peccatori J; Bonifazi F; Petrucci MT; Milone G; Guidi S; Giaccone L; Rotta M; Fanin R; Boccadoro M; Corradini P;
Haematologica; 2006 Jun; 91(6):837-9. PubMed ID: 16769588
[TBL] [Abstract][Full Text] [Related]
8. [Bortezomib in multiple myeloma patients after allogeneic stem cell transplantation].
Vokurka S
Klin Onkol; 2010; 23(4):242-4. PubMed ID: 20806822
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide.
Musto P; Falcone A; Sanpaolo G; Guglielmelli T; Zambello R; Balleari E; Catalano L; Spriano M; Cavallo F; La Sala A; Mantuano S; Nobile M; Melillo L; Scalzulli PR; Dell'Olio M; Bodenizza C; Greco MM; Carella AM; Merla E; Carella AM; Boccadoro M; Cascavilla N; Palumbo A
Leuk Res; 2006 Mar; 30(3):283-5. PubMed ID: 16111749
[TBL] [Abstract][Full Text] [Related]
10. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma.
Qazilbash MH; Saliba R; De Lima M; Hosing C; Couriel D; Aleman A; Roden L; Champlin R; Giralt SA
Cancer; 2006 Mar; 106(5):1084-9. PubMed ID: 16456814
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report.
Kaposztas Z; Kahan BD; Katz SM; Van Buren CT; Cherem L
Transplant Proc; 2009 Dec; 41(10):4407-10. PubMed ID: 20005409
[TBL] [Abstract][Full Text] [Related]
12. New developments in the treatment of patients with multiple myeloma.
Minnema MC; van der Spek E; van de Donk NW; Lokhorst HM
Neth J Med; 2010 Jan; 68(1):24-32. PubMed ID: 20103818
[TBL] [Abstract][Full Text] [Related]
13. Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma.
Kortüm M; Knop S; Einsele H
Future Oncol; 2011 Jan; 7(1):135-43. PubMed ID: 21174544
[TBL] [Abstract][Full Text] [Related]
14. Treatment of multiple myeloma: an emphasis on new developments.
Kyle RA; Vincent Rajkumar S
Ann Med; 2006; 38(2):111-5. PubMed ID: 16581696
[TBL] [Abstract][Full Text] [Related]
15. Treatment of multiple myeloma in the targeted therapy era.
Saad AA; Sharma M; Higa GM
Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
[TBL] [Abstract][Full Text] [Related]
16. Skin lesions induced by bortezomib.
Pour L; Hajek R; Zdenek A; Krejci M; Krivanova A; Vorlicek J
Haematologica; 2005 Dec; 90(12 Suppl):ECR44. PubMed ID: 16464759
[TBL] [Abstract][Full Text] [Related]
17. Advances in therapy of multiple myeloma.
Bladé J; Rosiñol L
Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053
[TBL] [Abstract][Full Text] [Related]
18. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
[TBL] [Abstract][Full Text] [Related]
19. Initial therapy in multiple myeloma: investigating the new treatment paradigm.
Kettle JK; Finkbiner KL; Klenke SE; Baker RD; Henry DW; Williams CB
J Oncol Pharm Pract; 2009 Sep; 15(3):131-41. PubMed ID: 19276138
[TBL] [Abstract][Full Text] [Related]
20. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]